Stock info Transgenomic Inc | Filter  Basic-Info

Transgenomic Inc

The past year yielded positive returns for Transgenomic Inc investors

Over the past year the company' stock lost around 73 percent. The period between August 2011 and August 2016 was a bad period for the investors. The stock lost around 98 percent. Transgenomic Inc's revenues between 2011 and 2015 were very fluctuating and moved between 31,48 million dollars and 1,65 million dollars. Transgenomic Inc's net results between 2011 and 2015 were relatively steady and moved between -9,78 million dollars and -10,14 million dollars.

Transgenomic Inc is mostly active in the biotech sector. The global biotech companies gained over the past 10 years on average 59 percent. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Transgenomic Inc financed with relatively low debt

At the end of 2015 the biotech company's balance sheet was worth 4,82 million dollars. 17,64 million dollars (365,98 percent of the total balance sheet) was financed by debt. The American company's price/earnings-ratio was -2. So the market valued the stock at -2 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the biotech company equaled around 10,84 million dollars. At the end of 2015 the American company had around 12,32 million stocks listed on the stock exchange(s).

All Transgenomic Inc's annual reports can be found here. More information about Transgenomic Inc can be found it's website. .